HOLX HOLOGIC INC

Nasdaq hologic.com


$ 74.00 $ 0.10 (0.14 %)    

Friday, 24-Oct-2025 15:59:54 EDT
QQQ $ 617.36 $ 6.52 (1.07 %)
DIA $ 472.05 $ 4.92 (1.05 %)
SPY $ 677.18 $ 5.49 (0.82 %)
TLT $ 91.38 $ 0.04 (0.04 %)
GLD $ 378.37 $ -1.27 (-0.34 %)
$ 73.99
$ 73.90
$ 73.11 x 1
$ 74.72 x 700
$ 73.87 - $ 74.11
$ 51.90 - $ 84.39
5,162,678
na
16.46B
$ 0.43
$ 29.54
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-28-2025 10-Q
2 05-02-2025 03-29-2025 10-Q
3 02-06-2025 12-28-2024 10-Q
4 11-27-2024 09-28-2024 10-K
5 07-30-2024 06-29-2024 10-Q
6 05-03-2024 03-30-2024 10-Q
7 02-02-2024 12-30-2023 10-Q
8 11-21-2023 09-30-2023 10-K
9 08-01-2023 07-01-2023 10-Q
10 05-02-2023 04-01-2023 10-Q
11 02-01-2023 12-31-2022 10-Q
12 11-15-2022 09-24-2022 10-K
13 07-27-2022 06-25-2022 10-Q
14 04-27-2022 03-26-2022 10-Q
15 02-02-2022 12-25-2021 10-Q
16 11-16-2021 09-25-2021 10-K
17 07-28-2021 06-26-2021 10-Q
18 04-28-2021 03-27-2021 10-Q
19 01-27-2021 12-26-2020 10-Q
20 11-17-2020 09-26-2020 10-K
21 07-29-2020 06-27-2020 10-Q
22 04-29-2020 03-28-2020 10-Q
23 01-29-2020 12-28-2019 10-Q
24 11-27-2019 09-28-2019 10-K
25 07-31-2019 06-29-2019 10-Q
26 05-01-2019 03-30-2019 10-Q
27 01-30-2019 12-29-2018 10-Q
28 11-20-2018 09-29-2018 10-K
29 07-31-2018 06-30-2018 10-Q
30 05-02-2018 03-31-2018 10-Q
31 02-08-2018 12-30-2017 10-Q
32 11-21-2017 09-30-2017 10-K
33 08-02-2017 07-01-2017 10-Q
34 05-10-2017 04-01-2017 10-Q
35 02-03-2017 12-31-2016 10-Q
36 11-17-2016 09-24-2016 10-K
37 07-27-2016 06-25-2016 10-Q
38 04-27-2016 03-26-2016 10-Q
39 01-27-2016 12-26-2015 10-Q
40 11-19-2015 09-26-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mizuho-downgrades-hologic-to-neutral-raises-price-target-to-78

Mizuho analyst Anthony Petrone downgrades Hologic (NASDAQ:HOLX) from Outperform to Neutral and raises the price target from ...

 raymond-james-downgrades-hologic-to-market-perform

Raymond James analyst Andrew Cooper downgrades Hologic (NASDAQ:HOLX) from Outperform to Market Perform.

 stephens--co-downgrades-hologic-to-equal-weight-lowers-price-target-to-76

Stephens & Co. analyst Mason Carrico downgrades Hologic (NASDAQ:HOLX) from Overweight to Equal-Weight and lowers the pri...

 jp-morgan-downgrades-hologic-to-neutral-announces-78-price-target

JP Morgan analyst Casey Woodring downgrades Hologic (NASDAQ:HOLX) from Overweight to Neutral and announces $78 price target.

 leerink-partners-maintains-market-perform-on-hologic-raises-price-target-to-78

Leerink Partners analyst Puneet Souda maintains Hologic (NASDAQ:HOLX) with a Market Perform and raises the price target from...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-10-21/citi-barclays-among-banks-leading-hologic-12-billion-d

 hologic-agrees-to-183-billion-buyout-by-blackstone-and-tpg

Hologic shares rose after announcing an $18.3B buyout by Blackstone and TPG, including a $3 CVR linked to Breast Health revenue...

 needham-reiterates-hold-on-hologicto-hold

Needham analyst Mike Matson reiterates Hologic (NASDAQ:HOLX) from Hold to Hold.

Core News & Articles

- SEC Filing

 hologic-shares-resume-trade
Hologic Shares Resume Trade
10/21/2025 13:06:43

Core News & Articles

Hologic Stockholders to Receive $76 per Share in Cash Plus a Contingent Value Right of up to $3 per Share Payable Upon Achievin...

 evercore-isi-group-upgrades-hologic-to-outperform-raises-price-target-to-78

Evercore ISI Group analyst Vijay Kumar upgrades Hologic (NASDAQ:HOLX) from In-Line to Outperform and raises the price target...

 hologic-receives-fda-510k-clearance-and-ce-mark-for-panther-fusion-gastrointestinal-bacterial-and-expanded-bacterial-assays-to-enhance-rapid-diagnosis-of-infectious-gastroenteritis

New Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays deliver tailored, actionable diagnostic results to ...

Core News & Articles

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it ha...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION